Medtronic and Genzyme Combine Their Cell Therapy Approaches to Serious Heart Disease
Executive Summary
To help guide it through the world of cardiac biologics, Medtronic's enlisted the help of biotech Genzyme. Medtronic has drug delivery devices and imaging expertise: Genzyme offers focused cell therapy research in cardiac repair and heart disease and has an up-and-running Phase II trial using autologous skeletal myoblasts. Both companies label the deal as strategic--for now. But 2006 is presumably the earliest newly formed MG Biotherapeutics will begin to commit heavily to this problematic endeavor.
You may also be interested in...
Reinventing Cell Therapy And Biomaterials
A profound redefinition of the role of many cell types and biomaterials in regenerative medicine is under way as researchers have moved away from the notion that cells introduced into the body will integrate and become functioning tissue.
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.
Medtronic: Doing Just What the Doctors Order
Medtronic has recruited physician opinion leaders for strategic management positions in most of its operating divisions. The company believes this strategy will help bring them closer to customers and expedite the bedside-to-bench process for developing new products.